pirinixic acid

Pirinixic acid (WY-14643) is a synthetic, selective and potent agonist of the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARα), with an EC50 of ~0.63 μM for PPARα and significantly less activity at PPARγ and PPARδ[1][2][6][7]. It is widely used as an experimental tool to study PPARα-mediated biological processes, including lipid metabolism, anti-inflammatory activity, and energy homeostasis[1][2][6]. Pirinixic acid has been shown to reduce NF-κB transcriptional activity, decrease inflammation, induce "browning" of white adipocytes when combined with retinoic acid, and exert effects on amyloid precursor protein processing in animal models[2][6]. It is not approved for clinical use and is restricted to laboratory research. Pirinixic acid was discovered as WY-14,643 in 1974 and was initially developed in the pharmaceutical industry as a hypolipidemic agent[4][7].

Other names

4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid2-[4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanylacetic acidpirnixic acid[4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid